Did You Know...
...that after Parker Brothers executives turned down the game of Monopoly because it had "52 fundamental errors" (including taking too long to play), a copy of the game wound up in the home of the company president who stayed up until 1 a.m. to finish playing it? He was so impressed by the game that the next day he wrote to inventor Charles Darrow and offered to buy it!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7396649 | Migraine and vasodilation treatment The present invention related to the use of Cystatin in predicting onset of migraines. The invention also relates to the use of Cystatin as a vasodilatory agent. The invention also relates to antagonists to Cystatin for use in treating and preventing and treating mi... | 07/08/2008 |
| 7182962 | Immunostimulator for animals and humans, and method of preventing animal and human infectious diseases and cancer The goal of the present invention is to provide substances to prevent diseases by activating inherently possessed functions, for cultured fishes and shellfishes and livestock with tendency of decreased immune function due to densely populated breeding environment, a... | 02/27/2007 |
| 7087719 | Method for the crystallization of human serum albumin The present invention relates to the purification and production of human albumin from various sources through crystallization and repeated crystallization. Basic features of the invented process include providing specific reaction conditions and precipitating reage... | 08/08/2006 |
| 7022744 | Ion exchanger for lipoproteins separation and lipoproteins separation method using the same A composition useful for separating lipoproteins, such as high density lipoprotein (HDL), low density lipoprotein (LDL), very low density lipoprotein (VLDL) and modified lipoproteins with a high degree of accuracy by ion-exchange based procedures. The composition co... | 04/04/2006 |
| 6967239 | Method of filtering viruses from a factor VIII solution Method for preparing a factor VIII solution that is essentially free of viruses and essentially devoid of vWF (von Willebrand factor) and factor VIII-vWF complexes by (a) obtaining a starting factor VIII solution devoid of factor VIII-vWF complexes; and (b) filterin... | 11/22/2005 |
| RE38827 | Adhesive sealant composition This invention is related to an adhesive composition which may be used to bond or seal tissue in vivo. The adhesive composition is readily formed from a two component mixture which includes a first part of a protein, preferably a serum albumin protein, in an aqueous... | 10/11/2005 |
| 6936423 | Anti-LTNF for in vitro assay of biological toxins Lethal Toxin Neutralizing Factor has been isolated in purity from opossum serum by high pressure liquid chromatography (HPLC) fractionation. The amino acid sequence from the N-terminal for the first fifteen amino acids of LTNF-n is: Leu Lys Ala Met Asp Pro Thr Pro P... | 08/30/2005 |
| 6924267 | Methods and active substances for protecting organs The present invention comprises a method of protecting organs or tissue susceptible to reperfusion-induced dysfunction after ischemia. The method comprises parenterally administering to a patient a therapeutical composition containing natural alpha-1 acid glycoprote... | 08/02/2005 |
| 6867193 | Amino acid-containing albumin preparation An albumin preparation that prevents onset of hepatic encephalopathy caused by conventional amino acid preparations and enhances an effect of improving the symptoms is provided. The albumin preparation containing amino acids is characterized in that a content of alb... | 03/15/2005 |
| 6841371 | Protein C derivatives Novel human protein C derivatives are described. These derivatives have increased anti-coagulation activity and resistance to inactivation by serpins, compared to wild-type protein C and retain the biological activity of the wild-type human protein D. These derivati... | 01/11/2005 |
| 6770278 | Methods of making and using immunoglobulin (Ig) compositions The invention is directed to methods of using Ig compositions to prevent and/or treat humans, livestock and/or domesticated animals suffering from stress induced respiratory disorders. The Ig composition comprises a concentrated amount of one or more immunoglobulins... | 08/03/2004 |
| 6719984 | Composition and method for immunomodulation in mammals This invention relates to compositions and processes utilized to modulate the immune system of mammals. More particularly, the present invention relates to the use of low molecular weight substantially immunoglobulin free fractions isolated from mammals to induce a ... | 04/13/2004 |
| 6716434 | Composition and method for immunostimulation in non- mammalian vertebrates This invention relates to compositions utilized to modulate the immune system of non-mammalian vertebrates. More particularly, the present invention relates to the use of low molecular weight substantially immunoglobulin free fractions isolated from mammals to induc... | 04/06/2004 |
| 6627404 | Methods for improving the recovery of troponin I and T in membranes, filters and vessels A method to facilitate recovery troponin I and/or troponin T from a sample comprising addition of troponin C to the sample or to a surface from which the troponin I and/or troponin T are recovered.... | 09/30/2003 |
| 6596691 | Therapeutic uses of BPI protein products for human meningococcemia Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.... | 07/22/2003 |
| 6586400 | Human therapeutic uses of BPI protein products Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated in... | 07/01/2003 |
| 6525176 | Purification of alpha-1 proteinase inhibitor A method for purifying human or other alpha-l proteinase inhibitor (댑 -PI) from a solution (which may be derived from the milk of a transgenic animal expressing the 댑 -PI) which comprises contacting the solution with a ... | 02/25/2003 |
| 6284871 | Factor IX binding peptides, derived from factor VIII and their use as inhibitors of blood coagulation The present invention relates to biologically active peptides which specifically inhibit the Factor IX-dependent pathway of blood coagulation. These peptides are based on a specific motif which represents a sequence of Factor VIII (amino acid 1811-1818) i... | 09/04/2001 |
| 6242418 | Therapeutic uses of BPI protein products for human meningococcemia Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.... | 06/05/2001 |
| 6191112 | Human therapeutic uses of BPI protein products Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated in... | 02/20/2001 |
| 6124431 | Peptide derivatives A peptide derivative represented by the following formula or a salt thereof ##STR1## wherein A represents a hydrogen atom, and B represents a phenyl group substituted with a hydroxyl group; said derivative has an antitumor activity stronger than that of d... | 09/26/2000 |
| 6100072 | Recombinant rabbit tissue factor based prothrombin time reagent Liquid and lyophilized reagents for determining prothrombin time and/or fibrinogen levels in a plasma sample are disclosed. The reagents preferably are based on recombinant rabbit tissue factor. Also disclosed is a purified preparation of recombinant rabb... | 08/08/2000 |
| 6093804 | Method for purification of alpha-1 proteinase inhibitor The methods of the present invention provide a simple means for separating active and inactive Alpha Proteinase Inhibitor (API). The methods further provide means for purifying API at high yield (>70%), and at levels of purity (>90%) and activity (>90%) n... | 07/25/2000 |
| 6037457 | Method for recombinant fibrinogen production The present invention provides methods of producing recombinant fibrinogen in a long-term mammalian cell culture system. Disclosed is a method for the production of recombinant fibrinogen, comprising: growing mammalian cells that express recombinant fibri... | 03/14/2000 |
| 6037450 | Diagnostic assays using soluble endothelial cell protein C/activated protein C receptor Plasma EPCR has been isolated, characterized and shown to block cellular protein C activation and APC anticoagulant activity. Plasma EPCR appears to be about 43,000 daltons and circulates at approximately 100 ng/ml (98.4&#b1;27.8 ng/ml, n=22). Plasma EPCR... | 03/14/2000 |
| 5990079 | Agents affecting thrombosis and hemostasis Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are... | 11/23/1999 |
| 5990086 | Therapeutic uses of BPI protein products for human meningococcemia Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.... | 11/23/1999 |
| 5968897 | Agents affecting thrombosis and hemostasis Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are... | 10/19/1999 |
| 5952302 | Human therapeutic uses of BPI protein products Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated in... | 09/14/1999 |
| 5939389 | Use of C1-inactivation for therapy of certain diseases The use of C1-inactivator for the production of a pharmaceutical for the prophylaxis and treatment of capillary leak syndrome (generalized extravasation) and circulator shock (refractory hypotension) in severe burns or scalds, in polytrauma, in operations... | 08/17/1999 |
| 5939529 | Methods and kits for stimulating production of megakaryocytes and thrombocytes The invention provides methods for stimulating thrombocytopoiesis in a mammal comprising administering to the mammal an effective amount of modified C-reactive protein ("mCRP") or mutant protein expressing neo-CRP antigenicity. Methods for treating thromb... | 08/17/1999 |
| 5925738 | Methods of production and use of liquid formulations of plasma proteins The present invention relates to the preparation and use of liquid formulations of plasma proteins, particularly blood coagulation factors. More specifically, the present invention relates to stable liquid formulations of Factor VIII and Factor IX that ca... | 07/20/1999 |
| 5919908 | Protein formulation comprising coagulation factor VIII or factor IX in an aqueous solution A final drug product comprises a plasma protein selected from the group consisting of coagulation factor VIII and factor IX, in an aqueous solution. The concentration of oxygen in the solution is reduced and/or the solution contains an antioxidant. The so... | 07/06/1999 |
| 5837679 | Agents affecting thrombosis and hemostasis Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are... | 11/17/1998 |
| 5831026 | Process for purifying factor VIII A process for reducing degradation of recombinant coagulation factor VIII caused by metal-dependent proteases requiring Zn2+ for activity or containing Zn2+ as an integral part of their structure comprises adding an inhibitor of Zn... | 11/03/1998 |
| 5831025 | Human activated protein C and process for preparing same A human Activated Protein C preparation with a high specific activity of 3500 U/mg or more and substantially free from thrombin or other proteases which can convert Protein C into Activated Protein C is provided. A process for preparing this human Activat... | 11/03/1998 |
| 5773417 | Human serum albumin-porphyrin complexes with the ability to bind oxygen and therapeutic uses thereof The invention is directed to human serum albumin-porphyrin (HSA-P) complexes which are capable of reversible oxygen binding and their uses. These complexes may be used in applications requiring physiological oxygen carriers such as in blood substitute sol... | 06/30/1998 |
| 5770199 | Method for virus inactivation in the presence of polyalkylene glycol as well as the pharmaceutical preparation obtained therewith The invention relates to a pharmaceutical preparation comprising a plasma protein wherein said preparation is free of infectious agents as well as essentially free of denaturation products and is obtainable by a method that encompasses the following steps... | 06/23/1998 |
| 5753620 | Human therapeutic uses of BPI protein products Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated in... | 05/19/1998 |
| 5744449 | Lethal toxin neutralizing factors Opossum whole serum exhibits a life saving property by neutralizing the lethality of venoms from all major families of poisonous snakes, and therefore an injection of Opossum serum can used as a novel treatment for many types of envenomation. Preferably, ... | 04/28/1998 |
